FIELD: medicine.
SUBSTANCE: the present innovation depicts the series of chimeric analogs of somatostatin-dopamine that keep activity of somatostatin and dopamine in vivo, for example: 6-n-propyl-8β-ergolinylmethylthioacetyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH2.
EFFECT: higher efficiency.
17 cl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
| CHIMERIC EQUIVALENTS OF LIGANS OF SOMATOSTATIN AND DOPERMINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS BASED ON THEM AND MODALTIES OF SOMATOSTATIN AND/DOPERMINE RECEPTORS | 2004 |
|
RU2329273C2 |
| CONJUGATES OF CYTOTOXIC AGENTS WITH PEPTIDES | 2007 |
|
RU2457218C2 |
| PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN-DOPAMINE CONJUGATES | 2009 |
|
RU2464039C2 |
| METHOD FOR MODULATING CELL PROLIFERATION OF THYROID MEDULLARY CARCINOMA | 2005 |
|
RU2317824C2 |
| METHOD OF MODULATION OF PROLIFERATION OF CELLS OF THYROID GLAND MEDULLARY CARCINOMA | 2002 |
|
RU2352578C2 |
| ANALOGS OF CYCLIC SOMATOSTATIN | 1999 |
|
RU2242481C2 |
| METHOD FOR MODULATING CELL PROLIFERATION OF MEDULLARY THYROID CARCINOMA | 2002 |
|
RU2275934C2 |
| NEUROMEDIN AND SOMATOSTATIN RECEPTOR AGONISTS | 2000 |
|
RU2263680C2 |
| NEW OCTAPEPTIDE COMPOUNDS AND THEIR THERAPEUTIC APPLICATION | 2011 |
|
RU2595525C2 |
